Navigation Links
Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
Date:12/12/2008

han 40%) in adult patients receiving either PEGINTRON or PEGINTRON/REBETOL are injection site inflammation/reaction, fatigue/asthenia, headache, rigors, fevers, nausea, myalgia, and anxiety/emotional lability/irritability. Most common adverse reactions (more than 25%) in pediatric patients receiving PEGINTRON/REBETOL are pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema and vomiting.

In a study with PEGINTRON/REBETOL (weight-based) combination therapy in adult patients, anemia with weight-based dosing was 29%; however, the majority of these cases were mild and responded to dose reductions. The incidence of serious adverse reactions reported for the weight-based REBETOL group was 12%. In many but not all cases, adverse reactions resolved after dose reduction or discontinuation of therapy. Some patients experienced ongoing or new serious adverse reactions during the 6-month follow-up period. Discontinuations for adverse events were 15% and were related to known interferon effects of psychiatric, systemic (e.g., fatigue, headache), or gastrointestinal adverse reactions. Dose modifications due to adverse reactions occurred in 29% of patients.

Most common adverse reactions with PEGINTRON/REBETOL (weight-based) combination therapy were psychiatric which occurred among 68-69% of patients. These psychiatric adverse reactions included most commonly depression, irritability, and insomnia, each reported by approximately 30-40% of subjects in all treatment groups. Suicidal behavior (ideation, attempts and suicides) occurred in 2% of all patients during treatment or during follow-up after treatment cessation. PEGINTRON induced fatigue or headache in approximately two-thirds of patients, with fever or rigors in approximately half of the patients. The severity of some of these systemic symptoms (e.g., fever and headache) tends to decrease as treatment continues. There was a 23-24% incidence overall for
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... array of instruments available for quantitative PCR (qPCR) in the last ... higher throughput and reduced operating costs. On the flipside, where do lab managers, ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... 27, 2015 , ... The Naderi Center is proud to announce that its ... procedure to improve submental fat. The first and only Food and Drug Administration ... Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, Virginia area ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... CEL-SCI Corporation (NYSE AMEX: CVM ) announced today financial results ... results: , , ... of 41% compared to a net loss of $3,210,294 during the same quarter ... loss per common share for the quarter ended March 31, 2009 was $0.02 ...
... 15 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: ... quarter ended March 31, 2009. Amounts, unless specified ... accordance with Canadian Generally Accepted Accounting Principles (Canadian ... 2009, the exchange rate was CAD$1.00=US$0.7928.Results of OperationsWe ...
... PARIS, FRANCE The International Union for Health ... Health Education (SOPHE) are pleased to release today special, ... and quality assurance systems of global capacity in health ... Education & Behavior (Vol. 36, No. 3, June ...
... Help Employers and Business Owners Plan for Pandemic ImpactPLYMOUTH ... hosting two free webinars on May 19, 2009 to ... Following the webinar Health Advocate will release a special ... summarizing steps for employers to take.Two experts - ...
... May 15 Within weeks, the University of ... campus that will provide a springboard for new discoveries, ... wise investment for U-M,s future.U-M,s purchase of the former ... North Campus will be completed on June 16, said ...
... of Medicine (BUSM) have found a high frequency ... the largest neonatal intensive care units (NICUs) in ... methods could reduce the vast number of hospital ... in the journal Infection Control and Hospital ...
Cached Medicine News:Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 2Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 3Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 4Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 5Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Special journal issues released on global health promotion and health education 2Health News:Experts to Discuss Worksite Preparedness Measures During May 19th Pandemic Flu Webinars 2Health News:U-M Purchase of Former Pfizer Facility Nears Completion, Paving the Way For Research Expansion and Job Creation 2Health News:BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units 2
(Date:8/27/2015)... CHICAGO and SOUTH SAN ... -- The Pulmonary Fibrosis Foundation (PFF) and ... announced that the organizations are partnering on a ... diagnostic experiences with interstitial lung diseases (ILDs), including ... Patient Journey (INTENSITY) survey will assess the steps ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... the "Company"), a biopharmaceutical company focused on the development ... it will release its year-end financial results for the ... 4, 2015. DelMar,s management team will ... for investors, analysts and other interested parties on Friday, ...
(Date:8/27/2015)... August 27, 2015 The global ... reach USD 3.96 billion by 2022, according to a ... of chronic venous disorders such as deep vein thrombosis, ... serve as the key driver.      (Logo: ... injuries are also expected to boost market growth over ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from ... presented,strong evidence today that an antibiotic typically prescribed ... types of cancers. , Q. Ping Dou, Ph.D., ... lab announced the findings of their study showing,that ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM ... of preclinical,data strongly supportive of the development ... demonstrates very high,bioavailability when administered orally; in ... well suited to oral,administration. These data were ...
Cached Medicine Technology:Alzheimer's Drug Shows Promise in Fighting Cancer 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3
Express Elyte Systems....
... 1650 has minimal requirements for ... 2 L/test), reagent consumption (as ... water consumption (25 L/hour) - ... universal rack handler facilitates continuous ...
Iron Total (TIBC) (Iron Buffer + Iron Color=Std.). An Automated analyzer test kits....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Medicine Products: